HOLD

• Forward P/E at 24x exists because market is paying for 59% earnings growth that hasn't materialized yet - this is a premium with embedded execution risk, not a discount
• ROE of 102% is a top-of-cycle metric vulnerable to compression from GLP-1 ramp slowdown, pricing pressure, IRA hits, or manufacturing constraints; 30x P/B will mean-revert if ROE compresses
• Technical setup shows MACD negative, price below 10 EMA, 50 SMA, and Bollinger middle band simultaneously; 200 SMA at $1,070 is the only support holding structure
• Compressed volume can precede breakdowns just as easily as breakouts; lower-high pattern on thin volume is not inherently bullish
• Institutional coverage going quiet means reduced visibility into next catalyst; Q3 earnings in ~2 weeks with no information flow creates uncertainty, not opportunity
• Oral GLP-1 competition (5-7 year threat) gets priced in 6-12 months before launch; IRA Medicare negotiation is a present, expanding threat
• At $1,150 with stop at $1,070, a 5-7% position risks ~7% per position or 35-50 bps portfolio drawdown
• The 12-20% upside scenario assumes no multiple compression and clean macro tape; 200 SMA breach opens downside to $1,000 or below
• Recommended action: HOLD at $1,150, wait for 200 SMA test confirmation and MACD bullish crossover, add zone at $1,071-$1,100, trim zone at $1,236-$1,292

→ vs aggressive: Forward P/E compression to 24x is not a discount—it reflects payment for 59% unproven earnings growth with embedded execution risk, not quality at a reasonable price

→ vs aggressive: ROE of 102% is a peak-cycle metric; any slowdown in GLP-1 ramp, pricing pressure, IRA hit, or manufacturing constraint will compress ROE and cause the 30x P/B to mean-revert hard

→ vs aggressive: MACD histogram compression is indecision, not a bullish signal; lower-high pattern on compressed volume can precede breakdowns just as easily as breakouts

→ vs aggressive: Calling a stock 'forgotten' as a bullish signal is dangerous framing—data-starved environments mean institutional investors lack visibility into next catalyst, creating uncertainty rather than opportunity

→ vs aggressive: Oral GLP-1 competitive threat (5-7 year timeline) gets priced in 6-12 months before commercial launch; IRA Medicare negotiation is an ongoing, expanding threat, not a long-dated footnote

→ vs aggressive: The 12-20% upside assumes no multiple compression and clean macro; the 200 SMA at $1,070 is a single point of failure—if broken, downside opens to $1,000 or below; asymmetric R/R only holds if you assume the floor holds, which risk management does not

HOLD with tiered deployment plan: 1-1.5% starter tranche at current levels, scale-in zones at 1,108-1,130 and 1,071-1,100, 5% ceiling, stop at 1,065, trim 25-33% into 1,236-1,292, reduce gross exposure 20-25% into Q3 earnings

• Starter position of 1 to 1.5 percent of book at current levels; full ceiling is 5 percent of book
• Scale-in zone 1 at 1,108 to 1,130 with MACD bullish crossover confirmation
• Scale-in zone 2 at 1,071 to 1,100 with 200 SMA holding and bullish MACD trigger
• Hard stop at 1,065 absolute, below the 200 SMA
• Trim 25 to 33 percent of holdings into any rally toward 1,236 to 1,292
• Reduce gross exposure approximately 20 to 25 percent into Q3 earnings window to manage binary risk
• Forward P/E of 24x with 59 percent expected EPS growth and PEG of 1.14 is not expensive for this quality of franchise
• 38x trailing P/E is rich and leaves no margin for execution missteps
• 30x P/B is an accounting artifact due to R&D capitalization and reinvestment; economic book value is higher
• Competitor oral GLP-1 threat should be monitored as Phase 3 data could adjust the multiple 12-24 months ahead

→ vs aggressive: Survivorship bias argument - zero coverage does not equal undervalued; no visibility into Q3 earnings expectations; R/R math flawed because stops get run at 1,070 when tested intraday to 1,065, causing 35-50 basis points realized drawdown per position

→ vs conservative: Waiting for MACD crossover and 50 SMA confirmation means buying at 1,200+ not 1,150; 30x P/B is an accounting artifact due to R&D capitalization and cash reinvestment, not an economic reality; by demanding perfect timing without early risk, the framework is too rigid for a structural growth name